Ultragenyx Pharmaceutical (RARE) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 14, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and annual report before voting.

Voting matters and shareholder proposals

• Election of three directors: Emil D. Kakkis, M.D., Ph.D., Shehnaaz Suliman, M.D., and Daniel G. Welch, all recommended by the board.

• Approval sought for the Third Amended and Restated 2023 Incentive Plan.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay) included.

Board of directors and corporate governance

• Board recommends all director nominees for election at the annual meeting.